CLINICAL EVIDENCE

REGENPRP™-HA COMBINATION FOR KNEE OA: ZHANG 2025

MRI analysis demonstrated a significant reduction in bone marrow edema at 12 months with the RegenPRP™-HA combination prepared using Cellular Matrix.

Significant reduction in bone marrow edema versus HA alone at 12 months (p=0.030).

A randomized, double-blind controlled trial compared the clinical efficacy and structural MRI outcomes of the RegenPRP™-HA combination prepared with Cellular Matrix versus hyaluronic acid (HA) alone in patients with knee osteoarthritis. Participants received two intra-articular injections administered 2-4 weeks apart and were followed for 12 months.

  • Number of patients: 58 (29 HA+PRP, 29 HA)
  • Mean age: 57 years
  • Kellgren-Lawrence grade II-III knee osteoarthritis
  • Follow-up: 12 months
  • MRI evaluation using Whole-Organ MRI Score (WORMS) methodology

RESULTS

  • Both the RegenPRP™-HA and HA groups demonstrated improvements in pain and function over 12 months.
  • No significant between-group differences were observed for VAS pain scores, WOMAC scores, EQ-5D-5L, or total WORMS score at 12 months.
  • MRI assessment showed a significant reduction in bone marrow edema in the RegenPRP™-HA group compared with HA alone at 12 months (−0.7 vs +0.7; p=0.030).
  • The addition of PRP was associated with structural improvements detected on MRI despite similar clinical outcomes between treatment groups.

CONCLUSION

Both RegenPRP™-HA and HA alone improved pain and function in patients with grade II-III knee osteoarthritis over 12 months. While clinical superiority was not demonstrated, the RegenPRP™-HA combination prepared with Cellular Matrix was associated with a significant reduction in bone marrow edema on MRI, suggesting potential structural benefits.

About Us

Since 2003, Regen Lab SA has specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous platelet-rich plasma (PRP) from the patient's own blood for bedside procedures.

Milestones

2003 - Foundation
2010 - RegenKit first approval in bone graft
2013 - A new state-of-theart laboratory in Lausanne
2014 - Cellular Matrix first approval
2015 - Launch of Cellular Matrix in Europe

Vision

Founded in 2003, Regen Lab has become a global reference thanks to its commitment to innovation, quality, and the effectiveness of its therapeutic solutions. Here’s how we have transformed the medical landscape over the past two decades.

RegenPRP™

RegenPRP™ is a medical treatment that uses platelet-rich plasma from the patient's own blood to enhance and tissue regeneration.

RegenPRP™ - HA

RegenPRP™ - HA combination is an innovative treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

RegenPRP™ - ATS

RegenPRP™ combined with ATS (Autologous Thrombin Serum) is an advanced approach to tissue regeneration that uses autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.

RegenExtracell®

RegenExtracell is an innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).

RegenWound

RegenWound is a fully autologous solution prepared from the patient’s own blood, with the objective of providing a standardised and reproducible approach for clinical use.

Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EU-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.

Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.

Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.